ACVRL1 and breast carcinoma: The finding that ALK1 inhibition only reduced metastatic burden, but did not affect metastatic incidence in the E0771 model, is most likely attributable to the fact that treatment was started when mice were already in advanced stage breast cancer, i.e., with preexisting disseminated disease.